Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
T863
Cat. No.:
0225LY-0727
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
T-863 is an orally active agent that selectively binds the acyl-CoA site of DGAT1 to inhibit cellular triacylglycerol synthesis; it has been shown to improve insulin sensitivity and reduce liver triglycerides in obese mouse models.
Synonym:
DGAT-3; DGAT-1 inhibitor; 701232-20-4; Trans-4-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexaneacetic acid; Cis-4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexaneacetic acid; {(1r,4r)-4-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexyl}acetic acid; Cyclohexaneacetic acid, 4-(4-(4-amino-7,7-dimethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)phenyl)-, trans-
CAS No.:
701232-20-4
Compound CID:
9865421
Formula:
C22H26N4O3
Formula Weight:
394.47
Specification
Relative Density:
1.36 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
T863 can be used in biochemical studies to investigate the role of DGAT1 as a therapeutic target for treating metabolic syndromes.
Library Information
Target:
DGAT1
Receptor:
DGAT1
Pathways:
Metabolism
Plate Number:
AOCL-10
Plate Location:
d4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
41.67 mg/mL; 105.64 mM
